RDY Dr Reddys Laboratories Ltd

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

January, 2024

 

Commission File Number 1-15182

 

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

 

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x                                Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______

 

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

 

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ¨                                No x

 

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

 

 

 

EXHIBITS

 

Exhibit Number		Description of Exhibits
99.1		Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - change in Senior Management Personnel

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: January 10, 2024	By:	/s/ K Randhir Singh
		Name:  K Randhir Singh
		Title:    Company Secretary

 

 

 

 

Exhibit 99.1

 

Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507   Tel      : +91 40 4900 2900 Fax     : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com

 

January 10, 2024

 

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

 

Dear Sir/Madam,

 

Sub:

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - change in Senior Management Personnel

 

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we would like to inform the following changes in the Senior Management Personnel of the Company:

 

a)

Dr. Ranjana Pathak has resigned from her role as Global Head of Quality and Pharmacovigilance. She will cease to be a member of the Management Council and Senior Management Personnel of the Company, effective on January 12, 2024. The resignation letter received from Dr. Pathak is annexed herewith; and

 

b)

Mr. Krishna Venkatesh, currently Head Global - Injectable Operations is elevated to the role of Global Head – Quality and Pharmacovigilance, and is also inducted as a Member of the Management Council and Senior Management Personnel of the Company, effective from January 12, 2024.

 

The details required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is given in Annexure enclosed herewith.

 

This is for your information and records.

 

Thanking you,

 

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer and Head-CSR

 

Encl: as above

 

 

 

 

Annexure

 

Details under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

 

Sl. No.	Particulars	Details
1	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	a)    Resignation of Dr. Ranjana Pathak from the role of Global Head of Quality and Pharmacovigilance. b)    Appointment of Mr. Krishna Venkatesh as a member of the Management Council and Senior Management Personnel of the Company.
2	Date of appointment/ re-appointment/  cessation (as applicable); and term of appointment/ re-appointment	a)   Dr. Ranjana Pathak has resigned from her role as Global Head of Quality and Pharmacovigilance. She will cease to be a member of the Management Council and Senior Management Personnel of the Company, effective on January 12, 2024. b)   Mr. Krishna Venkatesh, appointed as Global Head - Quality, and inducted as a Member of Management Council and Senior Management Personnel of the Company, effective from January 12, 2024. The Board of the Directors has approved the induction of Mr. Venkatesh as a Member of the Management Council and Senior Management Personnel of the Company on January 10. 2024.
3	Brief profile (in case of appointment)	a)    Not applicable b)   Mr. Krishna Venkatesh has ~28 years of experience. He joined the organization in March 2010 after stints in Barr Pharma and Teva in the US. He has a rich experience in product development, technical services, process engineering, tech transfer and scale ups. In his current role he has turned around the injectables operations significantly. He holds an MS in Pharmaceutics from University of Mississippi and is a graduate from BITS Pilani.
4	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

 

 

 

 

Date: January 10, 2024

 

To:

 

Dr. Reddy’s Laboratories Limited

8-2-337, Road No-3, Banjara Hills

Hyderbabad-Telangana-500034

 

Dear Erez,

 

Sub: Resignation

 

I hereby tender my resignation from my role of Global Head of Quality and Pharmacovigilance of Dr. Reddy’s Laboratories Limited. I would be relocating back to the US.

 

I sincerely appreciate the opportunity to work with the organization and have truly enjoyed the role. I wish the Company great success in the future.

 

Thanking you and regards,

 

/s/ Dr. Ranjana B Pathak
Dr. Ranjana B Pathak

 

 

---